A carregar...
SHP2 inhibition reduces leukemogenesis in models of combined genetic and epigenetic mutations
In patients with acute myeloid leukemia (AML), 10% to 30% with the normal karyotype express mutations in regulators of DNA methylation, such as TET2 or DNMT3A, in conjunction with activating mutation in the receptor tyrosine kinase FLT3. These patients have a poor prognosis because they do not respo...
Na minha lista:
| Publicado no: | J Clin Invest |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Clinical Investigation
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6877323/ https://ncbi.nlm.nih.gov/pubmed/31682240 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI130520 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|